Last updated: March 10, 2026
What is NDC 00093-7384?
NDC 00093-7384 refers to a specific drug identified by the National Drug Code (NDC) assigned by the FDA. According to available data, this NDC corresponds to Amoxapine Oral Tablet. This medication is used for managing depression and related psychiatric conditions.
Market Size and Demand
Therapeutic Class: Tricyclic antidepressant (TCA)
Indicated Population:
- Estimated prevalence of depression in the U.S.: approximately 17.3 million adults annually (2019 data)[1].
- Amoxapine accounts for less than 1% of antidepressant prescriptions, due to shifts towards SSRIs and SNRIs.
- Annual prescription volume for amoxapine remains below 1 million units.
Market Segments:
- Outpatient psychiatric clinics
- Hospitals
- Long-term care facilities
- Generic drug market (70% of prescription volume for antidepressants)
Key Competitors:
- Amitriptyline
- Nortriptyline
- Imipramine
- Other TCAs
Market Trends:
- Decrease in TCA prescriptions due to ADRs and availability of newer agents.
- Uptake mostly in patients intolerant to SSRIs/SNRIs, or with specific treatment-resistant depression.
- Growing interest in older medications for niche indications, especially in formulary-restricted environments.
Price Analysis
Historical Pricing Data
| Year |
Average Wholesale Price (AWP) per 30-Tablet Pack |
Notes |
| 2020 |
$45.00 |
Competitive generic pricing |
| 2022 |
$41.00 |
Slight decline, market saturation |
| 2023 |
$39.50 |
Stabilization, increased generic supply |
Market Price Comparisons
- Brand equivalent: No brand name exists; chemical synthesis entirely generic.
- Generic price range (per 30 tablets, 25 mg): $35-$50 depending on pharmacy and discounts.
- Insurance rebates: Typical rebates (~10-15%) reduce consumer price for insured patients.
Price Projections (2023-2028)
| Year |
Projected Wholesale Price (per 30 tablets) |
Assumptions |
| 2024 |
$38.00 |
Continued generic competition, stable demand |
| 2025 |
$36.00 |
Slight price decline, increased importation |
| 2026 |
$34.50 |
Market saturation, further competitor entries |
| 2027 |
$33.50 |
Cost pressures, pricing consolidation |
| 2028 |
$32.50 |
Entry of biosimilar or alternative therapies |
Factors Influencing Price Trends
- Generic supply: An increase in generic manufacturers could push prices downward.
- Regulatory changes: Expanded indications or formulations could affect market dynamics.
- Reimbursement policies: Stricter insurance criteria can pressure prices downward.
- Manufacturing costs: Price stability correlates with raw material and production costs.
Future Market Opportunities
- Repurposing for off-label uses in neuropathic pain or sleep disorders.
- Development of sustained-release formulations or combination therapies.
- Entry into markets with less developed generic drug infrastructure.
Risks and Challenges
- Declining use in depression treatment limits growth.
- Competition from newer antidepressants.
- Price erosion driven by patent expirations (not applicable here, as generic already dominates).
- Regulatory restrictions or formulary exclusions.
Key Takeaways
- NDC 00093-7384 corresponds to amoxapine, a largely legacy antidepressant.
- Market size remains small, with annual prescription volume below 1 million units.
- Pricing trends indicate gradual decline, stabilized at around $32-$39 per 30-tablet pack through 2028.
- Competitive pressures and shifts toward newer medications limit revenue growth.
- Opportunities reside mainly in niche applications and formulary niche markets.
FAQs
Q1: What therapeutic areas does NDC 00093-7384 serve?
A1: It primarily treats depression, especially in cases where patients are intolerant to SSRIs and SNRIs.
Q2: Is there potential for price increases?
A2: Limited, due to oversupply and decreasing demand; slight upward pressure may occur if supply decreases or reformulations emerge.
Q3: How does competition affect pricing?
A3: The presence of multiple generics drives prices down. Increased manufacturing capacity could further reduce prices.
Q4: Are there any regulatory changes affecting this drug?
A4: No recent changes have impacted amoxapine, but regulatory shifts around mental health medication access could influence demand.
Q5: Which markets could see growth?
A5: Niche markets, such as treatment-resistant depression or off-label uses, may offer limited growth opportunities.
References
[1] Substance Abuse and Mental Health Services Administration. (2020). Results from the 2019 National Survey on Drug Use and Health. https://www.samhsa.gov/data/report/2019-nsduh-annual-national-report
